Compare CNDT & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | BCYC |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.6M | 476.6M |
| IPO Year | N/A | 2019 |
| Metric | CNDT | BCYC |
|---|---|---|
| Price | $1.94 | $7.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.73 |
| AVG Volume (30 Days) | ★ 1.2M | 272.8K |
| Earning Date | 11-07-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,072,000,000.00 | $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.72 | $6.03 |
| 52 Week High | $4.90 | $15.47 |
| Indicator | CNDT | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 50.84 |
| Support Level | $1.97 | $6.73 |
| Resistance Level | $2.08 | $7.50 |
| Average True Range (ATR) | 0.10 | 0.37 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 29.18 | 46.74 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.